Vascular and tumour targeting programme

NGR-hTNF is the first molecule resulting from MolMed’s vascular and tumour targeting programme.  Another molecule issued from the programme is NGR-IFN-gamma, resulting from the linkage of the NGR peptide with the cytokine interferon-gamma, now in preclinical development.  Similarly to NGR-hTNF, this candidate is designed to specifically target the antitumour activity of IFN? onto tumour blood vessels.

The vascular and tumour targeting programme, in view of feeding MolMed’s anticancer pipeline, has as its objective the exploration of other possible targeting molecules, either to tumour blood vessels or to tumour tissues, along with effector molecules with strong antitumour activity.  The programme is based upon the identification and validation of targeting moieties and of appropriate effector molecules to conjugate to or to be administered in combination.